Can DaVita's Management Reconcile the Miss With Their Growth Narrative?

DaVita Inc. (DVA) reports first-quarter 2026 earnings after the close on May 5, 2026, with analysts expecting $2.41 per share on revenue of $3.33 billion. The central question: can the dialysis giant sustain the momentum from its strong Q4 beat and deliver on elevated growth expectations, or will operational headwinds resurface? With the stock trading near analyst price targets and technical indicators flashing bullish signals, this report will test whether DaVita's recent turnaround has staying power.

Part 1: Earnings Preview

DaVita Inc. operates the largest network of outpatient dialysis centers in the United States, providing kidney care services to patients with chronic kidney failure and end-stage renal disease. The company's business model centers on treatment volume, payor mix, and reimbursement rates—metrics that directly drive profitability in a heavily regulated healthcare environment.

DaVita reports Q1 2026 results after the close on May 5, 2026, with the Street expecting $2.41 per share and $3.33 billion in revenue. The company most recently reported $3.40 per share for Q4 2025, beating estimates by 4.94%. Year-over-year, the Q1 consensus represents 20.50% growth versus the $2.00 reported in Q1 2025, reflecting optimism that DaVita has turned a corner after last year's Q3 stumble.

Three key themes define this earnings story:

Treatment Volume and Same-Center Growth: Investors will scrutinize total treatment counts and same-center patient growth, the lifeblood of DaVita's revenue engine. Any acceleration in patient volumes—driven by demographic trends or market share gains—would validate the bullish growth estimates. Conversely, softness here could signal competitive pressure or patient retention challenges.

Payor Mix and Reimbursement Dynamics: The proportion of commercially insured versus government-reimbursed patients remains critical, as commercial rates deliver significantly higher margins. Management commentary on Medicare reimbursement changes and any shifts in payor mix will directly impact profitability forecasts. Recent regulatory stability has been a tailwind, but investors remain vigilant for policy shifts.

Operating Margin Expansion: With revenue growth accelerating, the focus turns to whether DaVita can translate top-line gains into margin improvement. Cost-control initiatives, center-level efficiency, and labor expense management will be under the microscope, especially as the company navigates a tight healthcare labor market.

Analyst commentary ahead of the release reflects cautious optimism. One analyst noted that DaVita "rarely misses Wall Street's revenue estimates," pointing to the company's consistent execution. However, the majority of analysts have maintained rather than raised estimates over the past 30 days, suggesting a wait-and-see posture. The Q3 2025 miss—where DVA reported $2.51 versus $3.29 expected, a -23.71% surprise—remains fresh in investors' minds, tempering enthusiasm despite the subsequent Q4 recovery.

Part 2: Historical Earnings Performance

DaVita's recent earnings track record reveals a company that has delivered more beats than misses, but with notable volatility in surprise magnitude. Over the past four quarters, DVA beat estimates three times and missed once, with the Q3 2025 shortfall standing out as a significant stumble.

The pattern shows Q1 2025 delivering a +14.29% surprise ($2.00 vs. $1.75 expected), followed by Q2 2025's +9.26% beat ($2.95 vs. $2.70). The Q3 2025 miss of -23.71% ($2.51 vs. $3.29) marked a sharp reversal, raising questions about operational consistency. However, Q4 2025 saw a return to form with a +4.94% beat ($3.40 vs. $3.24), suggesting the Q3 weakness was an anomaly rather than a trend.

The magnitude of beats has been modest in recent quarters—single-digit percentage surprises in Q2 and Q4—while the Q3 miss was substantial. This creates a mixed picture: DaVita generally meets or exceeds expectations, but when it misses, the shortfall can be material. Investors heading into Q1 2026 will be watching for confirmation that the Q4 recovery represents sustainable momentum rather than a one-quarter bounce.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

DaVita typically reports after market close, meaning Day 0 captures anticipatory moves before results drop, while Day +1 reflects the market's first full reaction to the actual numbers.

Historical price behavior around earnings reveals significant volatility, with the stock prone to sharp moves in either direction. The most recent Q4 2025 report exemplifies this: a modest +1.69% Day 0 move exploded into a +21.17% Day +1 surge, the largest single-day post-earnings gain in the dataset. This dramatic reaction followed the earnings beat and likely reflected relief that the Q3 stumble was behind the company.

The Q3 2025 miss produced a -2.35% Day 0 decline that extended to -6.17% by Day +1, while Q2 2025's beat saw an initial +0.72% gain reverse to -9.04% the following day—a reminder that even beats don't guarantee positive price action if guidance or commentary disappoints. Over the past eight quarters, the average absolute Day +1 move stands at 8.28%, with a Day 0 average of 1.49%, underscoring that the real action typically comes after investors digest the full report.

The wide Day +1 range of 8.28% suggests investors should brace for material price swings. Recent history shows DVA can move 10% or more in a single session post-earnings, with direction hinging not just on the EPS beat or miss, but on management's tone regarding volume trends, reimbursement outlook, and margin trajectory.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.55% expected move for the May 15 expiration, slightly above the 8.28% average absolute Day +1 move observed over the past eight quarters. This suggests options traders are anticipating volatility in line with—or modestly exceeding—recent historical norms, reflecting uncertainty about whether DaVita can sustain its Q4 momentum or if operational challenges will resurface.

Part 3: What Analysts Are Saying

Analyst sentiment on DaVita presents a cautious stance, with the consensus rating sitting at 3.13 (Hold territory) and an average price target of $151.00—just 2.1% below the current price of $154.08. The rating breakdown shows 1 Strong Buy, 6 Holds, and 1 Moderate Sell among the 8 analysts covering the stock, reflecting a lack of conviction in either direction.

Sentiment has deteriorated over the past month, with Strong Buy recommendations declining from 2 to 1 while Holds increased from 5 to 6. The average recommendation weakened from 3.38 to 3.13, signaling that analysts have grown more cautious heading into the Q1 report. This shift suggests some analysts may be taking a wait-and-see approach after the volatile performance in 2025.

The price target range spans $126.00 to $190.00, a wide spread that underscores divergent views on DVA's valuation. The $151.00 mean target implies minimal upside from current levels, suggesting the stock has largely priced in the consensus outlook. For bulls, the high-end $190.00 target represents 23.3% upside, but that view appears to be an outlier. The clustering of targets near current prices indicates analysts see the stock as fairly valued, with the upcoming earnings report serving as a potential catalyst to break the stalemate.

Part 4: Technical Picture

DaVita's technical setup heading into earnings reflects strengthening momentum, with the Barchart Technical Opinion registering 80% Buy—a significant improvement from 48% a week ago and 64% a month ago. This acceleration in bullish sentiment suggests technical traders are positioning for a positive outcome.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming, suggesting some consolidation or hesitation in the immediate timeframe
• Medium-term (100% Buy): Strong buy signal across the intermediate horizon reflects robust momentum building over recent weeks
• Long-term (100% Buy): Unanimous buy signal in the longer-term view indicates the broader trend has decisively turned bullish

Trend Characteristics: The Strong and Strengthening trend environment suggests DVA is building positive momentum across multiple timeframes, creating a supportive technical backdrop for the earnings release.

The stock is trading at $154.08, positioned above all key moving averages: the 5-day ($152.59), 10-day ($152.22), 20-day ($150.60), 50-day ($151.34), 100-day ($135.97), and 200-day ($132.94). This alignment—with price above every major moving average—is a classic bullish configuration, indicating uptrend support across short, intermediate, and long-term timeframes.

The technical picture is decidedly supportive heading into earnings, with DVA trading above all moving averages and technical indicators flashing buy signals across timeframes. The stock's position just above the $151.00 analyst price target and near recent highs suggests limited downside cushion if results disappoint, but the strengthening momentum could fuel a breakout if DaVita delivers a beat paired with constructive guidance. The 8.55% options-implied move provides a roadmap for potential volatility, with the $167.26 upper bound and $140.91 lower bound defining the expected trading range through mid-May.